DK2999715T3 - Nyt antistof som kan anvendes til neurologiske eller neurodegenerative lidelser - Google Patents

Nyt antistof som kan anvendes til neurologiske eller neurodegenerative lidelser Download PDF

Info

Publication number
DK2999715T3
DK2999715T3 DK14731163.3T DK14731163T DK2999715T3 DK 2999715 T3 DK2999715 T3 DK 2999715T3 DK 14731163 T DK14731163 T DK 14731163T DK 2999715 T3 DK2999715 T3 DK 2999715T3
Authority
DK
Denmark
Prior art keywords
neurological
neurodegenerative disorders
new antibody
antibody
new
Prior art date
Application number
DK14731163.3T
Other languages
English (en)
Inventor
Fabian Docagne
Richard Macrez
Denis Vivien
Karl-Uwe Petersen
Original Assignee
Inst Nat Sante Rech Med
Univ Caen
Paion Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Caen, Paion Deutschland Gmbh filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK2999715T3 publication Critical patent/DK2999715T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK14731163.3T 2013-05-21 2014-05-21 Nyt antistof som kan anvendes til neurologiske eller neurodegenerative lidelser DK2999715T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13002641 2013-05-21
EP13002850.9A EP2805972A1 (en) 2013-05-21 2013-06-03 Novel antibody useful in neurological or neurodegenerative disorders
PCT/EP2014/060486 WO2014187879A2 (en) 2013-05-21 2014-05-21 Novel antibody useful in neurological or neurodegenerative disorders

Publications (1)

Publication Number Publication Date
DK2999715T3 true DK2999715T3 (da) 2021-03-29

Family

ID=48463678

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14731163.3T DK2999715T3 (da) 2013-05-21 2014-05-21 Nyt antistof som kan anvendes til neurologiske eller neurodegenerative lidelser

Country Status (7)

Country Link
US (2) US10072077B2 (da)
EP (2) EP2805972A1 (da)
JP (2) JP6865581B2 (da)
DK (1) DK2999715T3 (da)
ES (1) ES2855973T3 (da)
PT (1) PT2999715T (da)
WO (1) WO2014187879A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis
CN110606887A (zh) * 2019-08-12 2019-12-24 陕西脉元生物科技有限公司 人体液中抗nmdar自身抗体的检测材料、制备方法及应用
CN116133684B (zh) 2020-05-27 2025-07-18 阿里亚利斯治疗公司 抗人nr1抗体衍生物
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
IL318503A (en) * 2022-07-29 2025-03-01 Arialys Therapeutics Inc Methods and systems for identifying or treating diseases of the central nervous system
WO2026020040A1 (en) * 2024-07-19 2026-01-22 Arialys Therapeutics, Inc. Methods of treating anti-nmdar antibody related disorders
WO2026033259A1 (en) * 2024-08-05 2026-02-12 Lys Therapeutics Antibodies for treating neurological and neurovascular disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
EP2289542A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders

Also Published As

Publication number Publication date
US20180371082A1 (en) 2018-12-27
JP2016531085A (ja) 2016-10-06
JP2019201655A (ja) 2019-11-28
US10072077B2 (en) 2018-09-11
US20160115230A1 (en) 2016-04-28
WO2014187879A3 (en) 2015-01-22
EP2805972A1 (en) 2014-11-26
JP6865581B2 (ja) 2021-04-28
ES2855973T3 (es) 2021-09-27
EP2999715A2 (en) 2016-03-30
PT2999715T (pt) 2021-03-24
WO2014187879A2 (en) 2014-11-27
EP2999715B1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
PL3556777T3 (pl) Konstrukty przeciwciał wieloswoistych
CL2015000214S1 (es) Automovil
CL2015001333S1 (es) Automovil
CL2015000719S1 (es) Automovil
IL291164A (en) Anti-nme antibody
CL2014003199S1 (es) Automovil
CL2015000718S1 (es) Automovil
CL2014002073S1 (es) Automovil
EP2837516A4 (en) COMMERCIAL VEHICLE
CL2015000468S1 (es) Automovil
LT3092003T (lt) Naujas anti-netrino-1 antikūnas
EP3009759A4 (en) COMMERCIAL VEHICLE
DK3122763T3 (da) Antimikrobielle peptiddendrimerer
LT3628731T (lt) Naujas antipresepsino antikūnas
CL2014001592S1 (es) Automovil
EP3550018A4 (en) NEW ENDO-SS-N-ACETYLGLUCOSAMINIDASE
HUE041870T2 (hu) Szûrõösszeállítás folyadékszûrõ számára
ES1135334Y (es) Coche volador
TH1401006417B (th) ยานพาหนะเเบบนั่งคร่อม
TH1401006288B (th) ยานพาหนะเเบบนั่งคร่อม
TH1401002900B (th) ยานพาหนะเเบบนั่งคร่อม
ES1142509Y (es) Fuelle para vehículos
ES1128880Y (es) Conjunto de escalera ocultable para vehiculos
TH1401004276B (th) มาตรรวมสำหรับยานพาหนะ
TH1601006445A (th) โครงสร้างสำหรับบรรจุของยานพาหนะ